COPD患者因肺炎住院后死亡率高于因急性加重住院
研究基于Salford Lung Study数据库,比较COPD患者因严重急性加重或肺炎住院后的死亡率,发现因肺炎住院后的死亡率显著高于因急性加重住院,提示在COPD症状急性恶化时准确诊断很重要。
要点
- COPD患者因肺炎住院后死亡率高于因急性加重住院。
- COPD症状急性恶化时需准确区分肺炎与急性加重。
- 管理计划和临床随访应考虑两者死亡风险差异。
核心结论
- COPD患者因肺炎住院后的死亡率显著高于因急性加重住院。
研究设计与样本
- 基于Salford Lung Study数据库,比较COPD患者因严重急性加重或肺炎住院后的死亡率。
主要发现
- 因肺炎住院后的死亡率显著高于因急性加重住院。
临床怎么用
- 在COPD症状急性恶化时进行准确诊断,以区分肺炎与急性加重。
- 制定管理计划和临床随访时考虑两者死亡风险差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mortality after an admission for pneumonia is considerably higher than for an admission for an exacerbation in COPD patients recruited from usual clinical practice. A proper diagnosis in acute worsenings of symptoms in COPD is therefore important. https://bit.ly/3LyhnnC Patients with COPD often experience exacerbations and pneumonia that are occasionally severe and lead to hospital admission [1–3]. The risk of pneumonia is further increased by treatment with inhaled corticosteroids (ICS) [4–6]. Although potentially difficult to distinguish [7], there could be differences in the risk of death associated with these events that need to be taken into account when planning management and clinical follow-up. The Salford Lung Study was set up to evaluate the effectiveness and safety of the once-daily inhaled combination of fluticasone furoate and vilanterol (FF/VI; in ELLIPTA dry powder inhaler) compared with existing maintenance therapy (usual care) in a large, real-world population of patients with COPD in conditions of normal care [8]. Strengths of the study include the relatively unselected patient population, the completeness of follow-up using a joint electronic record system and the fact that all patients were provided usual standard of care for their exacerbations and during admissions. We used this study database to examine mortality after an admission with a severe exacerbation or pneumonia, and the impact of classification of these events.
引用
- Vestbo J, Waterer G, Leather D, et al. Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. Eur Respir J. 2022. PMID: 35273031. doi:10.1183/13993003.02899-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。